This week in drug discovery (17-21 June) 

News round-up for 17-21 June by DDW Senior Digital Content Editor Diana Spencer.

It’s been another busy week in the world of cell therapy, with the first use of CAR-T therapy for stiff-person syndrome, a study debunking the risk of secondary cancers from CAR-T and a number of cell therapy research findings revealed at EHA2024.

The top stories:

Prize honours pioneers in CAR-T cell therapy

The 2024 Warren Alpert Foundation Prize has been awarded to four scientists whose discoveries led to the creation of chimeric antigen receptor (CAR)-T cells.

EHA2024: Industry shares latest drug research in blood cancers

A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June.

Risk of secondary cancers after CAR-T cell therapy just 6.5%

A large study has found that the risk of secondary blood cancers after CAR-T cell therapy is low, despite the Food and Drug Administration (FDA) warning.

First use of CAR-T therapy in patient with stiff-person syndrome

KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, has been used to treat a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS).

Phase II trial investigates allogeneic CAR-T for large B-cell lymphoma

Allogene Therapeutics and Foresight Diagnostics have announced the initiation of a Phase II trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) for newly diagnosed large B-cell lymphoma (LBCL) patients.

Listen to this round up on the DDW podcast:

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free